|
|
|
|
Our results show that IVT+MT patients in the ASTER trial have lower 90-day mortality compared with those receiving MT alone. In a selected population of patients without prestrike anticoagulation, we demonstrated that IVT associated with MT might improve functional outcome and recanalization while reducing mortality rates. |
|